Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes

Journal of Neurochemistry

Volumn 102, Issue 1, 2007, Pages 179-193

  Martire, Maria ^a   D'Amico, Monia ^a   Panza, Elisabetta ^b   Miceli, Francesco ^b   Viggiano, Davide ^b   Lavergata, Francesco ^a   Iannotti, Fabio Arturo ^b   Barrese, Vincenzo ^b   Preziosi, Paolo ^a   Annunziato, Lucio ^b   Taglialatela, Maurizio ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Dopamine release; KCNQ2 subunits; Modulation; Muscarinic; Potassium channels; Retigabine; Striatum

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; DOPAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE; PERTUSSIS TOXIN; PIRENZEPINE; POLYCLONAL ANTIBODY; POTASSIUM CHANNEL KCNQ2; POTASSIUM ION; PRESYNAPTIC RECEPTOR; PROTEIN ANTIBODY; RETIGABINE; TETRYLAMMONIUM; TRITIUM;

ABSORPTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CHO CELL; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINE RELEASE; EVOKED RESPONSE; MALE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

ANIMALS; BLOTTING, WESTERN; CARBAMATES; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE; ELECTROPHYSIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; KCNQ2 POTASSIUM CHANNEL; KCNQ3 POTASSIUM CHANNEL; MALE; MICROSCOPY, CONFOCAL; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; NEOSTRIATUM; NERVE ENDINGS; PATCH-CLAMP TECHNIQUES; PHENYLENEDIAMINES; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; RECEPTORS, PRESYNAPTIC; SYNAPTOSOMES;

RATTUS;

EID: 34250196164     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04562.x     Document Type: Article

References (59)

1. Blackburn-Munro G. Jensen B. S. (2003) The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. 460, 109 116.
2. Blackburn-Munro G., Dalby-Brown W., Mirza N. R., Mikkelsen J. D. Blackburn-Munro R. E. (2005) Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11, 1 20.
3. Bonanno G., Marchi M. Raiteri M. (1985) Activation of muscarinic receptors on striatal synaptosomes increases the release of endogenous dopamine. Neuropharmacology 24, 261 264.
4. Borgatti R., Zucca C., Cavallini A. et al. (2004) A novel mutation in KCNQ2 associated to BFNC, drug resistant epilepsy and mental retardation. Neurology 63, 57 65.
5. Brown D. A. Adams P. R. (1980) Muscarinic suppression of a novel voltage sensitive K+ current in a vertebrate neurone. Nature 283, 673 676.
6. Brown B. S. Yu S. P. (2000) Modulation and genetic identification of the M channel. Prog. Biophys. Mol. Biol. 73, 135 166.
7. Calabresi P., Cupini L. M., Centonze D., Pisani F. Bernardi G. (2003) Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann. Neurol. 53, 693 702.
8. Caulfield M. P. Birdsall N. J. (1998) International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279 290.
9. Cooper E. C., Aldape K. D., Abosch A., Barbaro N. M., Berger M. S., Peacock W. S., Jan Y. N. Jan L.Y. (2000) Colocalization and coassembly of two human brain M-Type potassium channel subunits that are mutated in epilepsy. Proc. Natl Acad. Sci. USA 97, 4914 4919.
10. Cooper E. C., Harrington E., Jan Y. N. Jan L. Y. (2001) M Channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J. Neurosci. 21, 9529 9540.
11. Delmas P. Brown D. A. (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat. Rev. Neurosci. 6, 850 862.
12. Devaux J. J., Kleopa K. A., Cooper E. C. Scherer S. S. (2004) KCNQ2 is a nodal K+ channel. J. Neurosci. 24, 1236 1244.
13. Di Chiara G., Morelli M. Consolo S. (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17, 228 233.
14. Dodson P. D. Forsythe I. D. (2004) Presynaptic K+ channels: electrifying regulators of synaptic terminal excitability. Trends Neurosci. 27, 210 217.
15. Eglen R. M., Choppin A. Watson N. (2001) Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 22, 409 414.
16. Freund T. F., Powell J. F. Smith A. D. (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13, 1189 1215.
17. Galindo C. A. Sitges M. (2004) Dihydropiridines mechanism of action in striatal isolated nerve endings: comparison with omega-agatoxin IVA. Neurochem. Res. 29, 659 669.
18. Guo J. Schofield G. G. (2003) Activation of muscarinic m5 receptors inhibits recombinant KCNQ2/KCNQ3 K+ channels expressed in HEK293T cells. Eur. J. Pharmacol. 462, 25 32.
19. Hadley J. K., Noda M., Selyanko A. A., Wood I. C., Abogadie F. C. Brown D. A. (2000) Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br. J. Pharmacol. 129, 413 415.
20. Hamilton S. E., Loose M. D., Qi M., Levey A. I., Hille B., McKnight G. S., Idzerda R. L. Nathanson N. M. (1997) Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Natl Acad. Sci. USA 94, 13311 13316.
21. Hansen H. H., Ebbesen C., Mathiesen C., Weikop P., Ronn L. C., Waroux O., Scuvee-Moreau J., Seutin V. Mikkelsen J. D. (2006) The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J. Pharmacol. Exp. Ther. 318, 1006 1019.
22. Harlow E. Lane D. (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Woodbury, NY, USA.
23. Jentsch T. J. (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. Neurosci. 1, 21 30.
24. Jerusalinsky D., Harvey A., Karlsson E. Potter L. (1997) Workshop: the use of muscarinic toxins in the study of muscarinic receptors. Life Sci. 60, 1161 1162.
25. Kornhuber J., Bleich S., Wiltfang J., Maler M. Parsons C. G. (1999) Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J. Neural Transm. 106, 857 867.
26. Korsgaard M. P., Hartz B. P., Brown W. D., Ahring P. K., Strobaek D. Mirza N. R. (2005) Anxiolytic effects of maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 314, 282 292.
27. Kristufek D., Koth G., Motejlek A., Schwarz K., Huck S. Boehm S. (1999) Modulation of spontaneous and stimulation-evoked transmitter release from rat sympathetic neurons by the cognition enhancer linopirdine: insights into its mechanisms of action. J. Neurochem. 72, 2083 2091.
28. Lechner S. G., Mayer M. Boehm S. (2003) Activation of M1 muscarinic receptors triggers transmitter release from rat sympathetic neurons through an inhibition of M-type K+ channels. J. Physiol. 553, 789 802.
29. Lehmann J. Langer S. Z. (1982) Muscarinic receptors on dopamine terminals in the cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine. Brain Res. 248, 61 69.
30. Main M. J., Cryan J. E., Dupere J. R., Cox B., Clare J. J. Burbidge S. A. (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 58, 253 262.
31. Marrion N. V. (1997) Control of M-current. Annu Rev Physiol 59, 483 504.
32. Martire M., Altobelli D., Maurizi S., Preziosi P. Fuxe K. (2000) K+-evoked [3H]D-Aspartate release in rat spinal cord synaptosomes: modulation by neuropeptide Y and calcium channel antagonists. J. Neurosci. Res. 62, 722 729.
33. Martire M., Castaldo P., D'Amico M., Preziosi P., Annunziato L. Tagliatatela M (2004) M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J. Neurosci. 24, 592 597.
34. Meir A., Ginsburg S., Butkevich A., Kachalsky S. G., Kaiserman I., Ahdut R., Demirgoren S. Rahamimoff R. (1999) Ion channels in presynaptic nerve terminals and control of transmitter release. Physiol. Rev. 79, 1019 1088.
35. Millan C., Lujan R., Shigemoto R. Sanchez-Prieto J. (2002) The inhibition of glutamate release by metabotropic glutamate receptor 7 affects both [Ca2+]c and cAMP: evidence for a strong reduction of Ca2+ entry in single nerve terminals. J. Biol. Chem. 277, 14092 14101.
36. Olianas M. C., Maullu C., Adem A., Mulugeta E., Karlsson E. Onali P. (2000) Inhibition of acetylcholine muscarinic M(1) receptor function by the M(1)-selective ligand muscarinic toxin 7 (MT-7). Br. J. Pharmacol. 131, 447 452.
37. Otto J. F., Kimball M. M. Wilcox K. S. (2002) Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol. Pharmacol. 61, 921 927.
38. Pan Z., Kao T., Horvath Z., Lemos J., Sul J. Y., Cranstoun S. D., Bennett V., Scherer S. S. Cooper E. C. (2006) A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J. Neurosci. 26, 2599 2613.
39. Passmore G. M., Selyanko A. A., Mistry M. et al. (2003) KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. 23, 7227 7236.
40. Peretz A., Degani N., Nachman R., Uziyel Y., Gibor G., Shabat D. Attali B. (2005) Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol. Pharmacol. 67, 1053 1066.
41. Raiteri L. Raiteri M. (2000) Synaptosomes still viable after 25 years of superfusion. Neurochem. Res. 25, 1265 1274.
42. Raiteri M., Marchi M. Maura G. (1982) Presynaptic muscarinic receptors increase striatal dopamine release evoked by "quasi-physiological" depolarization. Eur J Pharmacol 83, 127 129.
43. Raiteri M., Sala R., Fassio A., Rossetto O. Bonanno G. (2000) Entrapping of impermeant probes of different size into nonpermeabilized synaptosomes as a method to study presynaptic mechanisms. J. Neurochem. 74, 423 431.
44. Rapier C., Lunt G. G. Wonnacott S. (1990) Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation. J Neurochem 54, 937 945.
45. Rogawski M. A. (2000) KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends in Neurosci. 23, 393 398.
46. Rostock A., Tober C., Rundfeldt C. et al. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23, 211 223.
47. Rouse S. T., Hamilton S. E., Potter L. T., Nathanson N. M. Conn P. J. (2000) Muscarinic-induced modulation of potassium conductances is unchanged in mouse hippocampal pyramidal cells that lack functional M1 receptors. Neurosci. Lett. 278, 61 64.
48. Rundfeldt C. Netzer R. (2000) The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 282, 73 76.
49. Shah M. M., Mistry M., Marsh S. J., Brown D. A. Delmas P. (2002) Molecular correlates of the M-current in cultured rat hippocampal neurons. J. Physiol. 544, 29 37.
50. Shen W., Hamilton S. E, Nathanson N. M. Surmeier D. J. (2005) Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J. Neurosci. 25, 7449 7458.
51. Shieh C-C., Coghlan M., Sullivan J. P. Gopalakrishnan M. (2000) Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev. 52, 557 593.
52. Soldovieri M. V., Castaldo P., Iodice L. et al. (2006) Decreased subunit stability as a novel mechanism for potassium current impairment by a KCNQ2 C-terminus mutation causing benign familial neonatal convulsion. J. Biol. Chem. 281, 418 428.
53. Wang H. S., Pan Z., Shi W., Brown B. S., Wymore R. S., Cohen I. S., Dixon J. E. McKinnon D. (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282, 1890 1893.
54. Wen H. Levitan I. B. (2002) Calmodulin is an auxiliary subunit of KCNQ2/3 potassium channels. J. Neurosci. 22, 7991 8001.
55. Wess J. (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 44, 423 450.
56. Wickenden A. D., Yu W., Zou A., Jegla T. Wagoner P. K. (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 58, 591 600.
57. Xu M., Mizobe F., Yamamoto T. Kato T. (1989) Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain Res. 495, 232 242.
58. Zaczek R., Chorvat R. J., Saye J. A., Pierdomenico M. E., Maciag C. M., Logue A. R., Fisher B. N., Rominger D. H. Earl R. A. (1998) Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)- anthracenone and 10,10-bis(2-fluoro-4 pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. 285, 724 730.
59. Zhang W., Yamada M., Gomeza J., Basile A. S. Wess J. (2002) Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J. Neurosci. 22, 6347 6352.